De Novo 3q27.1 Microdeletion Refines the Critical Region and Implicates PSMD2 Haploinsufficiency in Growth and Neurodevelopmental Abnormalities
American Journal of Medical Genetics Part A · 2026-07 · 200 (7) · 1601-1607
DOI: 10.1002/ajmg.a.70097 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 10.03.2026. Verfasst von Eyyup Uctepe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Acibadem Labgen Genetic Diagnosis Center, Istanbul, Turkey. Hauptthemen laut MEDLINE: Chromosome Deletion, Haploinsufficiency, Intellectual Disability, Neurodevelopmental Disorders. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Interstitial deletions involving 3q27.1 define a distinct microdeletion syndrome characterized by prenatal‐onset growth restriction, postnatal microcephaly, hypotonia, intellectual disability, and distinctive craniofacial features. While AP2M1 haploinsufficiency has been proposed as the primary driver of this phenotype, the full spectrum of dosage‐sensitive genes within the locus remains unclear. Here, we report a patient with a de novo heterozygous 3q27.1 microdeletion and delineate a refined minimal smallest region of overlap (SRO) of approximately 189 kb, representing the narrowest critical interval associated with the 3q27.1 microdeletion phenotype to date. Chromosomal microarray and exome‐based CNV analysis confirmed the deletion, which encompasses PSMD2 , EIF4G1 , and POLR2H but excludes AP2M1 and DVL3 . The patient exhibited severe intrauterine growth restriction, microcephaly, global developmental delay, and mild dysmorphism, consistent with the established 3q27.1 phenotype. PSMD2 encodes a non‐ATPase regulatory subunit of the 26S proteasome, and its loss may disrupt proteasome‐mediated protein turnover and neuronal homeostasis. Comparison with previously published cases and an overlapping ClinVar variant (ID: 60129) with similar features supports the pathogenicity of this minimal deletion. Our findings refine the 3q27.1 critical region, propose PSMD2 haploinsufficiency as a likely molecular mechanism underlying growth and neurodevelopmental defects. Further cases and functional studies are needed to confirm PSMD2 causality and clarify the proteasome‐related mechanisms underlying 3q27.1 microdeletion syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Acibadem Labgen Genetic Diagnosis Center, Istanbul, Turkey.
- Department of Psychology, Dogus University, Faculty of Arts and Sciences, Istanbul, Turkey.
- Acibadem Maslak Hospital, Istanbul, Turkey.
ORCID-Profile: Eyyup Uctepe, Hanifenur Mancilar
Zitieren
APA
Uctepe, E., Esen, F. N., Mancilar, H., Tümer, S., Celebi, F., & Yesilyurt, A. (2026). De Novo 3q27.1 Microdeletion Refines the Critical Region and Implicates PSMD2 Haploinsufficiency in Growth and Neurodevelopmental Abnormalities. American Journal of Medical Genetics Part A, 200(7), 1601-1607. https://doi.org/10.1002/ajmg.a.70097
Vancouver
Uctepe E, Esen FN, Mancilar H, Tümer S, Celebi F, Yesilyurt A. De Novo 3q27.1 Microdeletion Refines the Critical Region and Implicates PSMD2 Haploinsufficiency in Growth and Neurodevelopmental Abnormalities. American Journal of Medical Genetics Part A. 2026;200(7):1601-1607. doi:10.1002/ajmg.a.70097
BibTeX
@article{Uctepe2026,
author = {Uctepe, Eyyup and Esen, Fatma Nisa and Mancilar, Hanifenur and Tümer, Sait and Celebi, Fahri and Yesilyurt, Ahmet},
title = {De Novo 3q27.1 Microdeletion Refines the Critical Region and Implicates PSMD2 Haploinsufficiency in Growth and Neurodevelopmental Abnormalities},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
volume = {200},
number = {7},
pages = {1601--1607},
doi = {10.1002/ajmg.a.70097}
}
EUVIMED